TY - JOUR
T1 - Recovery and maintenance of copper levels in geriatric patients on enteral feeding for a prolonged period
AU - Ito, Yuki
AU - Ando, Tetsuo
AU - Nabeshima, Toshitaka
PY - 2006/6
Y1 - 2006/6
N2 - Latent copper deficiency develops after 3 mo in patients receiving enteral feeding solutions with low copper levels. We examined whether a copper-rich enteral solution restores and maintains the level of copper in serum for a prolonged period. The study group consisted of 13 patients (eight males and five females). Commercial preparations, F2α® and Lifelon-PZ®, for enteral administration were used. F2α® and Lifelon-PZ® contain 1.6 and 0.13 mg/L, respectively, of copper. Serum copper levels were monitored in patients before and after administration of F2α®, a copper-rich enteral solution, at the neurological ward of Nagoya Daini Red Cross Hospital. Four of the 13 patients received Liflon-PZ®, a copper-poor enteral solution, before this trial. Blood samples were taken every month. The daily average copper dosage with F2α® was 1.8±0.4mg/d (1.0-2.4 mg/d). The copper level in the four patients who received Liflon-PZ® was 10.5 ±5.5 μmol/L before this trial. The level rose to 18.9±3.6 μmol/L 1 mo after the change to the copper-rich, F2α®. The average serum copper level in the other patients before the start of enteral feeding was 15.3±5.0 μmol/L. The proper copper level was maintained with F2α® in the long term. A copper-rich enteral preparation could easily restore and maintain serum copper levels for a prolonged period. A dose of 1.8±0.4 mg copper/d (1.0-2.4 mg/d) was sufficient for our patients.
AB - Latent copper deficiency develops after 3 mo in patients receiving enteral feeding solutions with low copper levels. We examined whether a copper-rich enteral solution restores and maintains the level of copper in serum for a prolonged period. The study group consisted of 13 patients (eight males and five females). Commercial preparations, F2α® and Lifelon-PZ®, for enteral administration were used. F2α® and Lifelon-PZ® contain 1.6 and 0.13 mg/L, respectively, of copper. Serum copper levels were monitored in patients before and after administration of F2α®, a copper-rich enteral solution, at the neurological ward of Nagoya Daini Red Cross Hospital. Four of the 13 patients received Liflon-PZ®, a copper-poor enteral solution, before this trial. Blood samples were taken every month. The daily average copper dosage with F2α® was 1.8±0.4mg/d (1.0-2.4 mg/d). The copper level in the four patients who received Liflon-PZ® was 10.5 ±5.5 μmol/L before this trial. The level rose to 18.9±3.6 μmol/L 1 mo after the change to the copper-rich, F2α®. The average serum copper level in the other patients before the start of enteral feeding was 15.3±5.0 μmol/L. The proper copper level was maintained with F2α® in the long term. A copper-rich enteral preparation could easily restore and maintain serum copper levels for a prolonged period. A dose of 1.8±0.4 mg copper/d (1.0-2.4 mg/d) was sufficient for our patients.
UR - http://www.scopus.com/inward/record.url?scp=33746934190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746934190&partnerID=8YFLogxK
U2 - 10.3177/jnsv.52.200
DO - 10.3177/jnsv.52.200
M3 - Article
C2 - 16967764
AN - SCOPUS:33746934190
SN - 0301-4800
VL - 52
SP - 200
EP - 204
JO - Journal of Nutritional Science and Vitaminology
JF - Journal of Nutritional Science and Vitaminology
IS - 3
ER -